A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Recruiting

Phase 3

Sponsor:

Jiangsu HengRui Medicine Co., Ltd.

Code:

NCT04691804

Conditions

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Fuzuloparib , Abiraterone acetate and Prednisone

Fuzuloparib Placebo， Abiraterone acetate and Prednisone

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information